Science and innovation

Check out our news

Get our newsletters

Published on the 10 November 2020

Our tau oligomer toxicity – a new tool for drug screening

The toxicity of the tau oligomers produced by ETAP-Lab can be reversed by using BDNF on primary rat neuron cultures. BNDF applied at the same time as tau oligomers significantly and reproducibly redu…

Science and innovation
Published on the 19 October 2020

Tau oligomer toxicity – our first data!

The new tau oligomers produced by ETAP-Lab show reproducible and dose-dependent toxicity on rodent primary neuron cultures. Promising and repeatedly replicated data show that tau oligomers exhibit …

Science and innovation
Published on the 7 September 2020

A first co-publication from PhIND and STROK@LLIANCE

We are delighted to share with you the results of the research conducted by Prof. Vivien’s PhIND team (UMR1237, ISERM, UniCaen, Caen), in collaboration with STROK@LLIANCE. A New Diagnostic Tool…

Science and innovation
Published on the 23 December 2019

A new stroke treatment developed by our academic partner is featured in the French newspaper l’Express.

For several years now, Prof. Denis Vivien’s team (Laboratoire PhIND, U1237, Caen), our STROK@LLIANCE partner, has been looking into in the potential of N-Acetylcysteine (NAC, Mucomyst®) for thrombolys…

Science and innovation
Published on the 10 October 2019

In vitro services are ready to test your drugs for neurodegenerative diseases!

Last June, we produced the first batch of beta-amyloid 1-42 oligomers in our new facilities, using our unique know-how for oligomer production and stabilization (see here). We are very happy and pr…

Science and innovation
Published on the 8 October 2019

New preclinical models of Heart Failure presented at the last edition of the GRRC

The participation to the « Spring of Cardiology » offered to Syncrosome the opportunity to present its expertise in the cardiovascular field: development of preclinical models of heart failu…

Science and innovation
Published on the 24 May 2019

Clinical evidence confirms Pep2Dia effects on postprandial glycemia in prediabetic subjects

ETAP-Lab had an instrumental position in Ingredia's projects and successfully predicted in mice the efficacy of Pep2Dia, a new bioactive ingredient expected to reduce postprandial blood sugar levels….

Science and innovation
Published on the 17 May 2019

Syncrosome at the next NeuroFrance Congress in Marseille

SYNCROSOME your dedicated partner for In Vivo Efficacy Studies has been accepted for a poster presentation at NeuroFrance 2019 (Marseille, France, 22-24 May) which is an International Meeting from Soc…

Events Science and innovation

Explore our scientific resources and browse posters…

Explore Our Resources